133 related articles for article (PubMed ID: 20467227)
1. [Molecular remission induced by gemtuzumab ozogamicin in an elderly patient with relapsed acute promyelocytic leukemia].
Yago K; Aono M; Shimada H
Rinsho Ketsueki; 2010 Apr; 51(4):286-90. PubMed ID: 20467227
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
Aribi A; Kantarjian HM; Estey EH; Koller CA; Thomas DA; Kornblau SM; Faderl SH; Laddie NM; Garcia-Manero G; Cortes JE
Cancer; 2007 Apr; 109(7):1355-9. PubMed ID: 17326049
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Ravandi F; Estey E; Jones D; Faderl S; O'Brien S; Fiorentino J; Pierce S; Blamble D; Estrov Z; Wierda W; Ferrajoli A; Verstovsek S; Garcia-Manero G; Cortes J; Kantarjian H
J Clin Oncol; 2009 Feb; 27(4):504-10. PubMed ID: 19075265
[TBL] [Abstract][Full Text] [Related]
4. Two patients with all-trans retinoic acid-resistant acute promyelocytic leukemia treated successfully with gemtuzumab ozogamicin as a single agent.
Takeshita A; Shinjo K; Naito K; Matsui H; Sahara N; Shigeno K; Suzumura T; Horii T; Shirai N; Maekawa M; Yada Y; Teshima H; Takeuchi J; Ohnishi K; Ohno R
Int J Hematol; 2005 Dec; 82(5):445-8. PubMed ID: 16533750
[TBL] [Abstract][Full Text] [Related]
5. Combination of all-trans-retinoic acid and gemtuzumab ozogamicin in an elderly patient with acute promyelocytic leukemia and severe cardiac failure.
Finizio O; Pezzullo L; Rocco S; Bene L; De Rosa C; Nunziata GR; Mettivier V
Acta Haematol; 2007; 117(3):188-90. PubMed ID: 17167240
[TBL] [Abstract][Full Text] [Related]
6. Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia.
Breccia M; Cimino G; Diverio D; Gentilini F; Mandelli F; Lo Coco F
Haematologica; 2007 Sep; 92(9):1273-4. PubMed ID: 17768126
[TBL] [Abstract][Full Text] [Related]
7. [Gemtuzumab ozogamicin successfully induced molecular remission in relapsed therapy-related acute promyelocytic leukemia].
Shimokawa T; Kojima Y
Rinsho Ketsueki; 2008 Apr; 49(4):270-2. PubMed ID: 18516871
[TBL] [Abstract][Full Text] [Related]
8. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
[TBL] [Abstract][Full Text] [Related]
9. Treatment of relapsed or refractory acute promyelocytic leukemia.
Tallman MS
Best Pract Res Clin Haematol; 2007 Mar; 20(1):57-65. PubMed ID: 17336255
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Tsimberidou AM; Estey E; Whitman GJ; Dryden MJ; Ratnam S; Pierce S; Faderl S; Giles F; Kantarjian HM; Garcia-Manero G
Leuk Res; 2004 Sep; 28(9):991-4. PubMed ID: 15234578
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of acute promyelocytic leukemia treated with all-
Abaza Y; Kantarjian H; Garcia-Manero G; Estey E; Borthakur G; Jabbour E; Faderl S; O'Brien S; Wierda W; Pierce S; Brandt M; McCue D; Luthra R; Patel K; Kornblau S; Kadia T; Daver N; DiNardo C; Jain N; Verstovsek S; Ferrajoli A; Andreeff M; Konopleva M; Estrov Z; Foudray M; McCue D; Cortes J; Ravandi F
Blood; 2017 Mar; 129(10):1275-1283. PubMed ID: 28003274
[TBL] [Abstract][Full Text] [Related]
12. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.
Breccia M; Lo-Coco F
Expert Opin Biol Ther; 2011 Feb; 11(2):225-34. PubMed ID: 21142804
[TBL] [Abstract][Full Text] [Related]
13. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.
Lo Coco F; Ammatuna E; Noguera N
Clin Adv Hematol Oncol; 2006 Jan; 4(1):57-62, 76-7. PubMed ID: 16562371
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.
Takeshita A; Shinjo K; Naito K; Matsui H; Sahara N; Shigeno K; Horii T; Shirai N; Maekawa M; Ohnishi K; Naoe T; Ohno R
Leukemia; 2005 Aug; 19(8):1306-11. PubMed ID: 15920495
[TBL] [Abstract][Full Text] [Related]
16. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia.
Lo-Coco F; Cimino G; Breccia M; Noguera NI; Diverio D; Finolezzi E; Pogliani EM; Di Bona E; Micalizzi C; Kropp M; Venditti A; Tafuri A; Mandelli F
Blood; 2004 Oct; 104(7):1995-9. PubMed ID: 15187030
[TBL] [Abstract][Full Text] [Related]
17. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
18. Sustained molecular remission after arsenic trioxide and gemutuzumab ozogamicin in a pediatric patient with relapsed acute promyelocytic leukemia.
Inoue A; Kawakami C; Takitani K; Tamai H
Pediatr Hematol Oncol; 2012 Mar; 29(2):170-2. PubMed ID: 22292427
[No Abstract] [Full Text] [Related]
19. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.
Leoni F; Gianfaldoni G; Annunziata M; Fanci R; Ciolli S; Nozzoli C; Ferrara F
Haematologica; 2002 May; 87(5):485-9. PubMed ID: 12010661
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
